3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
2
Phase 2
2
Phase 1/2
1
Status
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
1
Conditions
Hypertension
2
Diabetes Mellitus, Type 2
2
Cushing Syndrome
2
ACTH Syndrome, Ectopic
2
Pituitary ACTH Hypersecretion
1
Interventions
Cyclophosphamide
297
Cisplatin
297
Paclitaxel
258
Radiotherapy
253
Fluorouracil
234
Carboplatin
234
Docetaxel
231
Doxorubicin
212
Dexamethasone
164
Gemcitabine
155
Vincristine
143
Etoposide
133
Leucovorin
132
Capecitabine
129
Bevacizumab
129
Prednisone
124
Rituximab
118
Methotrexate
117
Cytarabine
108
Filgrastim
99
Trastuzumab
98
Oxaliplatin
96
pembrolizumab
81
Pemetrexed
73
Epirubicin
70
Tamoxifen
69
Drug Therapy
69
Irinotecan
65
Granulocyte Colony-Stimulating Factor
60
Nivolumab
57
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
relacorilant
×
Clear all
NCT04308590
2025-09-04
GRADIENT
Corcept Therapeutics
Phase 3
Completed
137 enrolled
25 charts
NCT03697109
2025-07-16
GRACE
Corcept Therapeutics
Phase 3
Completed
152 enrolled
28 charts